Lorena Franco-Martínez1, Fernando Tecles1, Alberto Torres-Cantero2, Enrique Bernal3, Indra San Lázaro2, María José Alcaraz3, María R Vicente-Romero4, Elsa Lamy5, Cristina Sánchez-Resalt6, Camila P Rubio1, Asta Tvarijonaviciute1, Silvia Martínez-Subiela1, José J Cerón1. 1. Interdisciplinary Laboratory of Clinical Analysis Interlab-UMU, Regional Campus of International Excellence Mare Nostrum, University of Murcia, Espinardo, Murcia, Spain. 2. Preventive Medicine, Hospital Clínico Universitario Virgen de la Arrixaca, IMIB, Universidad de Murcia, Murcia, Spain. 3. Unit of Infectious Diseases, Hospital General Universitario Reina Sofía, Universidad De Murcia, Murcia, Spain. 4. Unit of Microbiology, Hospital General Universitario Reina Sofía, Universidad De Murcia, Murcia, Spain. 5. Mediterranean Institute for Agriculture, Environment and Development (MED), Advanced Research and Training Institute (IIFA), University of Évora, Évora, Portugal. 6. Sport Medicine Centre, University of Murcia, Espinardo, Murcia, Spain.
Abstract
OBJECTIVES: The aim of the present study was to validate a commercially available automated assay for the measurement of total adenosine deaminase (tADA) and its isoenzymes (ADA1 and ADA2) in saliva in a fast and accurate way, and evaluate the possible changes of these analytes in individuals with SARS-CoV-2 infection. METHODS: The validation, in addition to the evaluation of precision and accuracy, included the analysis of the effects of the main procedures that are currently being used for SARS-CoV-2 inactivation in saliva and a pilot study to evaluate the possible changes in salivary tADA and isoenzymes in individuals infected with SARS-CoV-2. RESULTS: The automated assay proved to be accurate and precise, with intra- and inter-assay coefficients of variation below 8.2%, linearity under dilution linear regression with R2 close to 1, and recovery percentage between 80 and 120% in all cases. This assay was affected when the sample is treated with heat or SDS for virus inactivation but tolerated Triton X-100 and NP-40. Individuals with SARS-CoV-2 infection (n=71) and who recovered from infection (n=11) had higher mean values of activity of tADA and its isoenzymes than healthy individuals (n=35). CONCLUSIONS: tADA and its isoenzymes ADA1 and ADA2 can be measured accurately and precisely in saliva samples in a rapid, economical, and reproducible way and can be analyzed after chemical inactivation with Triton X-100 and NP-40. Besides, the changes observed in tADA and isoenzymes in individuals with COVID-19 open the possibility of their potential use as non-invasive biomarkers in this disease.
OBJECTIVES: The aim of the present study was to validate a commercially available automated assay for the measurement of total adenosine deaminase (tADA) and its isoenzymes (ADA1 and ADA2) in saliva in a fast and accurate way, and evaluate the possible changes of these analytes in individuals with SARS-CoV-2 infection. METHODS: The validation, in addition to the evaluation of precision and accuracy, included the analysis of the effects of the main procedures that are currently being used for SARS-CoV-2 inactivation in saliva and a pilot study to evaluate the possible changes in salivary tADA and isoenzymes in individuals infected with SARS-CoV-2. RESULTS: The automated assay proved to be accurate and precise, with intra- and inter-assay coefficients of variation below 8.2%, linearity under dilution linear regression with R2 close to 1, and recovery percentage between 80 and 120% in all cases. This assay was affected when the sample is treated with heat or SDS for virus inactivation but tolerated Triton X-100 and NP-40. Individuals with SARS-CoV-2 infection (n=71) and who recovered from infection (n=11) had higher mean values of activity of tADA and its isoenzymes than healthy individuals (n=35). CONCLUSIONS:tADA and its isoenzymes ADA1 and ADA2 can be measured accurately and precisely in saliva samples in a rapid, economical, and reproducible way and can be analyzed after chemical inactivation with Triton X-100 and NP-40. Besides, the changes observed in tADA and isoenzymes in individuals with COVID-19 open the possibility of their potential use as non-invasive biomarkers in this disease.
Authors: Elsa Lamy; Camila P Rubio; Laura Carreira; Fernando Capela E Silva; Silvia Martinez-Subiela; Fernando Tecles; Pia Lopez-Jornet; Jose J Ceron; Asta Tvarijonaviciute Journal: Sci Rep Date: 2022-06-08 Impact factor: 4.996
Authors: Lorena Franco-Martínez; José J Cerón; María R Vicente-Romero; Enrique Bernal; Alberto Torres Cantero; Fernando Tecles; Cristina Sánchez Resalt; Mónica Martínez; Asta Tvarijonaviciute; Silvia Martínez-Subiela Journal: Int J Environ Res Public Health Date: 2021-12-21 Impact factor: 3.390
Authors: Alberto Muñoz-Prieto; Ivana Rubić; Juan Carlos Gonzalez-Sanchez; Josipa Kuleš; Silvia Martínez-Subiela; José Joaquín Cerón; Enrique Bernal; Alberto Torres-Cantero; María Rosario Vicente-Romero; Vladimir Mrljak; Asta Tvarijonaviciute Journal: Sci Rep Date: 2022-06-27 Impact factor: 4.996